| Citation: |
CHEN Yao-lin, WANG Yin-man, FANG Da-wei, et al. Relationship between lipoprotein (a) and the severity of coronary artery disease and its influence on major adverse cardiovascular events[J]. Chin J Clin Med, 2021, 28(1): 70-74. DOI: 10.12025/j.issn.1008-6358.2021.20202220
|
To explore the correlation between lipoprotein (a) or Lp(a) and severity of coronary artery stenosis and its predictive value of major adverse cardiovascular events (MACE) in elderly patients with coronary artery disease (CAD).
A total of 693 elderly patients with CAD who were admitted to the Department of Cardiology, Zhongshan Hospital, Fudan University from January 2014 to December 2014 for percutaneous coronary intervention (PCI) were selected. The serum Lp (a) level was detected and the severity of coronary artery stenosis was calculated according to the Gensini score on patient admission. The serum Lp (a) level changes and MACE were followed up.
The patients were divided into three groups according to the Lp (a) levels. There was statistically significant difference (P < 0.05) in Gensini score among the three groups. The levels of LDL-C and InLp (a) were independently correlated with the degree of coronary artery stenosis after adjusting for multiple risk factors (P < 0.05). A total of 91 cases of MACE occurred during the follow-up, and Lp (a) level was an independent influencing factor of MACE (P < 0.05). According to whether MACE occurred or not, patients were divided into the MACE group and non-MACE group. LDL-C level was similar in the two groups at baseline and during follow-up. Lp (a) in MACE group was significantly higher than that in non-MACE group during follow-up (P < 0.05). The area under curve (AUC) of Lp (a) level was 0.582 (95% CI 0.511-0.652). The predicted sensitivity was 61.5%, and the specificity was 54.9% with a cut-off value of 151 mg/L (15.10 mg/mL) of the serum Lp (a).
Lp (a) may be an independent risk factor for predicting the degree of coronary stenosis in patients with CAD. Lp (a) level is related to the occurrence of MACE with the same level of LDL-C.
| [1] |
SCHMIDT K, NOUREEN A, KRONENBERG F, et al. Structure, function, and genetics of lipoprotein (a)[J]. J Lipid Res, 2016, 57: 1339-1359. DOI: 10.1194/jlr.R067314
|
| [2] |
NORDESTGAARD B G, CHAPMAN M J, RAY K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status[J]. Eur Heart J, 2010, 31(23): 2844-2853. DOI: 10.1093/eurheartj/ehq386
|
| [3] |
KAMSTRUP P R, TYBJAERG-HANSEN A, STEFFENSEN R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J]. JAMA, 2009, 301(22): 2331-2339. DOI: 10.1001/jama.2009.801
|
| [4] |
CLARKE R, PEDEN J F, HOPEWELL J C, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease[J]. N Engl J Med, 2009, 361(26): 2518-2528. DOI: 10.1056/NEJMoa0902604
|
| [5] |
MANITA D, YOSHIDA H, HIROWATAR Y. Cholesterol levels of six fractionated serum lipoproteins and its relevance to coronary heart disease risk scores[J]. J Atheroscler Thromb, 2017, 24(9): 928-939. DOI: 10.5551/jat.34728
|
| [6] |
NICHOLLS S J, TANG W H W, SCOFFONE H, et al. Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy[J]. J Lipid Res, 2010, 51(10), 3055-3061. DOI: 10.1194/jlr.M008961
|
| [7] |
KONISHI H, MIYAUCHI K, KASAI T, et al. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention[J]. Am J Cardiol, 2015, 115(2): 157-160. DOI: 10.1016/j.amjcard.2014.10.015
|
| [8] |
ALBERS J J, SLEE A, O'BRIEN K D, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)[J]. J Am Coll Cardiol, 2013, 62(17): 1575-1579. DOI: 10.1016/j.jacc.2013.06.051
|
| [9] |
LORENZATTI A, SERVATO M L. Role of anti-inflammatory interventions in coronary artery disease: understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)[J]. Eur Cardiol, 2018, 13(1): 38-41. DOI: 10.15420/ecr.2018.11.1
|
| [10] |
CAI A P, LI L W, ZHANG Y, et al. Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement[J]. Dis Markers, 2013, 35(6): 857-862.
|
| [11] |
KHERA A V, EVERETT B M, CAULFIELD M P, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial(justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)[J]. Circulation, 2014, 129(6): 635-642. DOI: 10.1161/CIRCULATIONAHA.113.004406
|
| [12] |
YANG S H, LI S, ZHANG Y, et al. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese[J]. J Endocrinol Invest, 2016, 39(8): 875-883. DOI: 10.1007/s40618-016-0433-9
|
| [13] |
GENCER B, KRONENBERG F, STROES E S, et al. Lipoprotein(a): the revenant[J]. Eur Heart J, 2017, 38(20): 1-8. http://smartsearch.nstl.gov.cn/paper_detail.html?id=ea14bedeb58c57858294368c9e6b0477
|
| [14] |
BITTNER V A, SZAREK M, AYLWARD P E, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome[J]. J Am Coll Cardiol, 2020, 75(2): 133-144. DOI: 10.1016/j.jacc.2019.10.057
|
DownLoad: